SU‐GG‐T‐505

Efficiency and Cost of RapidArc to Deliver Highly Heterogeneous Dose for Simultaneous Integrated Boost Plans: A Dosimetry Study

W. Yang, R. Jones, P. Read, J. Lamer, Stanley H Benedict, K. Sheng

Research output: Contribution to journalArticle

Abstract

Purpose: A set of parameters unique to heterogeneous dose distribution is used to standardize the evaluation of RapidArc (RA) for simultaneous integrated boost (SIB). Methods and Materials: RA plans were run on both phantom and patients. 30 Gy was prescribed to PTV and 35–90 Gy were prescribed to boost tumor volume (BTV) with varying size and location inside the PTV. Dose contrast, defined as the mean dose to the BTV divided by that of PTV, was used to evaluate the ability of RA system to escalate BTV doses without over‐treating the rest of PTV. A biological contrast was computed using biological equivalent dose (BED). To calculate standardized efficiency, both contrast indices were normalized to ideal cases that boost dose can be delivered without other changes to the plan. The integral dose to the entire phantom excluding PTV was used to assess the cost to other normal tissue. Five brain patients with SIB prescription were planned and analyzed based on the same methodology. SIB plans are subsequently compared with sequential boost (SEB) plans. Results: Efficiency decreases non‐linearly with the size of the BTV and the boost doses. An optimal boost dose at 45 Gy was observed using the metric. For BTVs located in the center of the PTV, the integral dose to the normal tissue increased by less than 5% comparing to the PTV only plan, and surprisingly stays almost constant with increasing boost doses. For BTVs close to the edge of PTV, the integral dose increased by 5–20% with boost dose. SIB plans are dosimetrically more favorable than SEB plans. The patient plans are consistent with phantom plans. Conclusion: The nonlinearity of cost and efficiency to delivery SIB plan was demonstrated, indicating the feasibility to selectively boost small tumor volume to a very high dose on the RapidArc platform.

Original languageEnglish (US)
Number of pages1
JournalMedical Physics
Volume37
Issue number6
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Tumor Burden
Costs and Cost Analysis
Prescriptions
Brain

ASJC Scopus subject areas

  • Biophysics
  • Radiology Nuclear Medicine and imaging

Cite this

SU‐GG‐T‐505 : Efficiency and Cost of RapidArc to Deliver Highly Heterogeneous Dose for Simultaneous Integrated Boost Plans: A Dosimetry Study. / Yang, W.; Jones, R.; Read, P.; Lamer, J.; Benedict, Stanley H; Sheng, K.

In: Medical Physics, Vol. 37, No. 6, 2010.

Research output: Contribution to journalArticle

@article{2b972c910f8f4f1181fd6112f1c8e829,
title = "SU‐GG‐T‐505: Efficiency and Cost of RapidArc to Deliver Highly Heterogeneous Dose for Simultaneous Integrated Boost Plans: A Dosimetry Study",
abstract = "Purpose: A set of parameters unique to heterogeneous dose distribution is used to standardize the evaluation of RapidArc (RA) for simultaneous integrated boost (SIB). Methods and Materials: RA plans were run on both phantom and patients. 30 Gy was prescribed to PTV and 35–90 Gy were prescribed to boost tumor volume (BTV) with varying size and location inside the PTV. Dose contrast, defined as the mean dose to the BTV divided by that of PTV, was used to evaluate the ability of RA system to escalate BTV doses without over‐treating the rest of PTV. A biological contrast was computed using biological equivalent dose (BED). To calculate standardized efficiency, both contrast indices were normalized to ideal cases that boost dose can be delivered without other changes to the plan. The integral dose to the entire phantom excluding PTV was used to assess the cost to other normal tissue. Five brain patients with SIB prescription were planned and analyzed based on the same methodology. SIB plans are subsequently compared with sequential boost (SEB) plans. Results: Efficiency decreases non‐linearly with the size of the BTV and the boost doses. An optimal boost dose at 45 Gy was observed using the metric. For BTVs located in the center of the PTV, the integral dose to the normal tissue increased by less than 5{\%} comparing to the PTV only plan, and surprisingly stays almost constant with increasing boost doses. For BTVs close to the edge of PTV, the integral dose increased by 5–20{\%} with boost dose. SIB plans are dosimetrically more favorable than SEB plans. The patient plans are consistent with phantom plans. Conclusion: The nonlinearity of cost and efficiency to delivery SIB plan was demonstrated, indicating the feasibility to selectively boost small tumor volume to a very high dose on the RapidArc platform.",
author = "W. Yang and R. Jones and P. Read and J. Lamer and Benedict, {Stanley H} and K. Sheng",
year = "2010",
doi = "10.1118/1.3468901",
language = "English (US)",
volume = "37",
journal = "Medical Physics",
issn = "0094-2405",
publisher = "AAPM - American Association of Physicists in Medicine",
number = "6",

}

TY - JOUR

T1 - SU‐GG‐T‐505

T2 - Efficiency and Cost of RapidArc to Deliver Highly Heterogeneous Dose for Simultaneous Integrated Boost Plans: A Dosimetry Study

AU - Yang, W.

AU - Jones, R.

AU - Read, P.

AU - Lamer, J.

AU - Benedict, Stanley H

AU - Sheng, K.

PY - 2010

Y1 - 2010

N2 - Purpose: A set of parameters unique to heterogeneous dose distribution is used to standardize the evaluation of RapidArc (RA) for simultaneous integrated boost (SIB). Methods and Materials: RA plans were run on both phantom and patients. 30 Gy was prescribed to PTV and 35–90 Gy were prescribed to boost tumor volume (BTV) with varying size and location inside the PTV. Dose contrast, defined as the mean dose to the BTV divided by that of PTV, was used to evaluate the ability of RA system to escalate BTV doses without over‐treating the rest of PTV. A biological contrast was computed using biological equivalent dose (BED). To calculate standardized efficiency, both contrast indices were normalized to ideal cases that boost dose can be delivered without other changes to the plan. The integral dose to the entire phantom excluding PTV was used to assess the cost to other normal tissue. Five brain patients with SIB prescription were planned and analyzed based on the same methodology. SIB plans are subsequently compared with sequential boost (SEB) plans. Results: Efficiency decreases non‐linearly with the size of the BTV and the boost doses. An optimal boost dose at 45 Gy was observed using the metric. For BTVs located in the center of the PTV, the integral dose to the normal tissue increased by less than 5% comparing to the PTV only plan, and surprisingly stays almost constant with increasing boost doses. For BTVs close to the edge of PTV, the integral dose increased by 5–20% with boost dose. SIB plans are dosimetrically more favorable than SEB plans. The patient plans are consistent with phantom plans. Conclusion: The nonlinearity of cost and efficiency to delivery SIB plan was demonstrated, indicating the feasibility to selectively boost small tumor volume to a very high dose on the RapidArc platform.

AB - Purpose: A set of parameters unique to heterogeneous dose distribution is used to standardize the evaluation of RapidArc (RA) for simultaneous integrated boost (SIB). Methods and Materials: RA plans were run on both phantom and patients. 30 Gy was prescribed to PTV and 35–90 Gy were prescribed to boost tumor volume (BTV) with varying size and location inside the PTV. Dose contrast, defined as the mean dose to the BTV divided by that of PTV, was used to evaluate the ability of RA system to escalate BTV doses without over‐treating the rest of PTV. A biological contrast was computed using biological equivalent dose (BED). To calculate standardized efficiency, both contrast indices were normalized to ideal cases that boost dose can be delivered without other changes to the plan. The integral dose to the entire phantom excluding PTV was used to assess the cost to other normal tissue. Five brain patients with SIB prescription were planned and analyzed based on the same methodology. SIB plans are subsequently compared with sequential boost (SEB) plans. Results: Efficiency decreases non‐linearly with the size of the BTV and the boost doses. An optimal boost dose at 45 Gy was observed using the metric. For BTVs located in the center of the PTV, the integral dose to the normal tissue increased by less than 5% comparing to the PTV only plan, and surprisingly stays almost constant with increasing boost doses. For BTVs close to the edge of PTV, the integral dose increased by 5–20% with boost dose. SIB plans are dosimetrically more favorable than SEB plans. The patient plans are consistent with phantom plans. Conclusion: The nonlinearity of cost and efficiency to delivery SIB plan was demonstrated, indicating the feasibility to selectively boost small tumor volume to a very high dose on the RapidArc platform.

UR - http://www.scopus.com/inward/record.url?scp=85024805096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024805096&partnerID=8YFLogxK

U2 - 10.1118/1.3468901

DO - 10.1118/1.3468901

M3 - Article

VL - 37

JO - Medical Physics

JF - Medical Physics

SN - 0094-2405

IS - 6

ER -